ARCA Biopharma slumps as experimental COVID drug fails to meet study goal

Oruka Therapeutics

31/03/2022 22:18

** ARCA Biopharma Inc's shares  ABIO.O  slump 28.3% to $1.65
in after-market trading
    ** Says its experimental treatment, rNAPc2, did not meet
primary goal in mid-stage trial of 160 hospitalized COVID-19
patients  urn:newsml:reuters.com:*:nGNX2V00R
    ** Adds that it is now evaluating options for development of
its assets, including partnering and other strategic options
    ** Up to Thursday's close, stock had risen 7% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))